Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers

by Abbassi, A., Adam, J., Bahleda, R., Baldini, C., Bigorgne, A., Boselli, L., Bredel, D., Cassard, L., Champiat, S., Chaput, N., Danlos, F.-X, Escriou, G., Farhane, S., Gazzah, A., Grivel, J., Grynszpan, L., Halse, H., Hollebecque, A., Lacroix, L., Laghouati, S., Marabelle, A., Martin-Romano, P., Massard, C., Michot, J.-M, Mohamed-Djalim, C., Mouraud, S., Parpaleix, A., Postel-Vinay, S., Rafie, S., Ribrag, V., Signolle, N., Soria, J.-C, Susini, S., Texier, M., Varga, A., Vuagnat, P., Zitvogel, L.
Published 2022